SciELO - Scientific Electronic Library Online

 
vol.29 issue4Brain injury after cardiac arrestLupoid sclerosis author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Acta Neurológica Colombiana

Print version ISSN 0120-8748

Abstract

BUSTOS SANCHEZ, Jose Luis  and  AYALA GARCIA, Martín Germán. Fingolimod for multiple sclerosis. Acta Neurol Colomb. [online]. 2013, vol.29, n.4, pp.266-273. ISSN 0120-8748.

Fingolimod was the first oral therapy for Multiple Sclerosis approved worldwide as a disease-modifying treatment for the relapsing-remitting form. It Is an immunosuppressant prodrug, homologue with sphingosine. The approval for its application has scientific support in two collaborative clinical trials: TRANSFORMS and FREEDOMS. Serious side effects reported during these studies (in more than two patients) were basal cell carcinoma, bradycardia within the first six hours of administration and lower respiratory tract infection. Two patients died: one of them with herpetic encephalitis and the other one of a varicella zoster infection. There is 0.3% risk of developing macular edema.

Keywords : Demyelinating; Autoinmune Disease; Inmunosuppression; Multiple Sclerosis; Recurrense (MeSH).

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )